Integrium to Attend Redefining Early Stage Investments Conference (RESI)


Media inquiries about Integrium Clinical Research or its services should be directed to:

Sheri Farsakh
Tel (657) 900-5232

Tustin, Calif. - September 15, 2014

Integrium is attending the Redefining Early Stage Investments (RESI) conference held September 17, 2014 in Boston, MA. With a goal to conduct capital efficient clinical trials, Integrium is connecting with investors and facilitating early-stage life science companies to grow at a progressive rate. The challenges involved in conceptualizing, funding, and growing an early-stage biotech can become overwhelming without the right resources.

The annual conference provides everyone in the market with the opportunity to educate and connect on behalf of early-stage life science investments. Early-stage biotechs are able to network with early-stage biotech investors of various practices and build relationships with service providers such as

Creating good networks and having strong advocates on your side is exceptionally powerful when facing the recent early stage funding gap. Integrium offers early-stage partners an all-inclusive package of services as a Clinical Proof of Concept firm with referral relationships in the bio ecosystem.

To meet with Mike Loftus at the RESI conference, please email or call (908) 295-4578.

About Integrium, LLC

Integrium Clinical Research specializes in the strategy, study design, and execution of Phase I-IV clinical trials, with an expertise in Proof of Concept trials. The firm has strong clinical trial experience in a range of therapeutic indications including cardiovascular, metabolic, renal, inflammatory, dermatology, regenerative, orphan, and wound healing drug development. It has a strong reputation for delivering high-quality management of global clinical development programs and service to its clients. Combining the Integrium Clinical Excellence (ICE) study start-up and management methodology, and therapeutic expertise leads sponsors to more confident, better-informed drug and device development decisions. For more information please visit